https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/biomarin-release-results-cln2-trial-being-carried-out-gosh/
Biomarin release results from CLN2 trial being carried out at GOSH
28 Jun 2016, 2:05 p.m.
Biomarin have released positive 48-week results from a clinical trial of cerliponase alfa treatment for CLN2 disease.
CLN2 disease is a form of Batten disease, a fatal neurodegenerative disease. It is the result of mutations in the TPP1/CLN2 gene causing deficient activity of the tripeptidyl peptidase 1 enzyme (TPP1). Cerliponase alfa treatment is a recombinant form of TPP1 and is designed to restore TPP1 enzyme activity.
In this Phase I/II trial, cerliponase alfa treatment was administered directly into the brain ventricles via intracerebroventricular infusions. At one year, the results have shown an 80 per cent reduction in the progression of the disease relating to decline in motor and language functioning, when compared to the natural progression of the disease. Furthermore, treatment was also found to reduce cortical grey matter loss.Biomarin plans to submit marketing applications and is planning to implement an early access programme to enable additional CLN2 patients to have access to this treatment.
The Great Ormond Street Hospital (GOSH) involvement in the trial was led by Novel Therapies Deputy Theme Lead, Professor Paul Gissen.
New study pinpoints why some transplanted kidneys are rejected
Researchers at University College London (UCL), the Wellcome Sanger Institute and the University of Cambridge combined technology that determines the genetic or RNA sequence of individual cells with powerful 3D imaging to look at lymphatic vessels
Scientists discover clues to help children with rare muscle disease
New ground-breaking research by experts at Great Ormond Street Hospital (GOSH) and University College London (UCL) has led to an exciting discovery that could help children with the rare muscle disease, juvenile dermatomyositis (JDM).
What do bush babies, tamarin monkeys, and mouse lemurs have that humans don’t?
GOSH imaging researchers have worked with teams in Harvard in the USA to work out how and when our pelvises developed to be different from other animals.
Nanodiamonds and hormones used in rare condition to promote lung growth
An international research team led by GOSH, UCL and KU Leuven in Belgium, is using 3D-printing and nanodiamonds, to design treatments that could help babies repair their damaged lungs in the womb.